Amphastar Pharmaceuticals, Inc. (AMPH) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Amphastar (AMPH) Q1 2026: New Launches Offset 15% Baximi Price Hit as Portfolio Mix Shifts
  May 08, 2026
• Amphastar (AMPH) Q4 2025: Ipratropium Bromide HFA Approval Unlocks 180 Days of Market Exclusivity
  February 27, 2026
• Amphastar (AMPH) Q3 2025: Proprietary Pipeline Now 50% of R&D, Pushing $60B Market Expansion
  November 07, 2025
• Amphastar (AMPH) Q3 2024: Gross Margin Slides 700bps as Baximi Transition Reshapes P&L
  November 06, 2024
• Amphastar (AMPH) Q2 2024: Gross Margin Lifts to 52.2% as Baximi and Epinephrine Outperform
  August 07, 2024
• Amphastar (AMPH) Q1 2024: Baximi Sales Jump 22% as Portfolio Integration Drives Expansion
  May 08, 2024

Browse all companies